SCHEMBL23478698

SCHEMBL23478698

CSCc1ccc2scnc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TRPM5 Q9NZQ8 1/20 0.38
FFAR1 O14842 1/20 0.38
PTK6 Q13882 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD11B1 P28845 1/20 0.35
KDR P35968 3/20 0.34
RIPK2 O43353 2/20 0.34
LCK P06239 2/20 0.34
TGFBR1 P36897 2/20 0.34
MAP3K11 Q16584 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HKDC1 Q2TB90 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2620993 0.80 NPC1 (0.47) ALDH1A1HSD17B10TRPM5FFAR1PTK6
SCHEMBL13610446 0.80 ALDH1A1 (0.39) ALDH1A1HSD17B10TRPM5FFAR1PTK6
SCHEMBL29976332 0.78 ALDH1A1 (0.47) ALDH1A1HSD17B10TRPM5FFAR1PTK6
SCHEMBL9676880 0.78 ALDH1A1 (0.47) ALDH1A1HSD17B10TRPM5FFAR1PTK6
SCHEMBL6647512 0.77 ALDH1A1 (0.42) ALDH1A1HSD17B10TRPM5FFAR1PTK6
SCHEMBL3819546 0.77 ALDH1A1 (0.45) ALDH1A1HSD17B10TRPM5FFAR1SMN1; SMN2
SCHEMBL9921443 0.77 ALDH1A1 (0.45) ALDH1A1HSD17B10TRPM5FFAR1PTK6
SCHEMBL2357662 0.77 HSD17B10 (0.50) ALDH1A1HSD17B10TRPM5FFAR1SMN1; SMN2
SCHEMBL6396893 0.77 CYP2A6 (0.47) ALDH1A1HSD17B10TRPM5FFAR1SMN1; SMN2
SCHEMBL13610284 0.77 ALDH1A1 (0.45) ALDH1A1HSD17B10TRPM5FFAR1PTK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 US disclosed
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4709/4885HSD17B10 3100/4885TRPM5 3761/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ALDH1A1 4709/4885HSD17B10 3100/4885TRPM5 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.